Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

By the end of the study, people on the maximum dose of Zepbound lost an average of about 50 ... lb (13.7 percent of their body weight) with Wegovy. More weight loss wasn’t the only advantage ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

People who took Zepbound had greater reductions in waist circumference and body weight, a study found.Fact checked by Nick ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Novo Nordisk told Reuters in a statement that a similar dose of Wegovy led to greater weight loss in a 2021 trial ... Zepbound shed about 50.3 pounds, on average, while those who used Wegovy ...